A Cross-Sectional Study in Patients with Severe COPD to Assess the Perception of Symptom Variability (COPVAR) in the Middle East and Africa

References

• World Health Organization. The top 10 causes of death; 2014 5 Available from: http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 130, 2019.
   Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s. doi:10.1183/09031936.03.0007800212795331
   PubMedGoogle Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–272. doi:10.1183/09031936.0005111021115606
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2015). Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed 322, 2019.
   Google Scholar
• Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231–238. doi:10.2147/COPD.S4286623687444
   PubMed Web of Science ®Google Scholar
• van den Berge M, Hop WC, van der Molen T, et al. Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res. 2012;13:44. doi:10.1186/1465-9921-13-4422672621
   PubMed Web of Science ®Google Scholar
• Partridge M, Karlsson N, Stahl E. Development of the Morning Activities and Symptoms Questionnaire (MASQ) for COPD. Eur Respir J. 2008;32:814s.
   Google Scholar
• Partridge MR, Miravitlles M, Ståhl E, et al. Development and validation of the capacity of daily living during the morning questionnaire and the global chest symptoms questionnaire in COPD. Eur Respir J. 2010;36:96–104. doi:10.1183/09031936.0012370919897551
   PubMed Web of Science ®Google Scholar
• Mapel DW, Dalal AA, Johnson PT, et al. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity. Int J Chron Obstruct Pulmon Dis. 2015;10:1477–1486.26251587
   PubMed Web of Science ®Google Scholar
• Safka KA, Wald J, Wang H, et al. GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstr Pulm Dis. 2016;4:45–55. doi:10.15326/jcopdf.4.1.2016.012628848910
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–1178. doi:10.1016/S0140-6736(09)61298-819716598
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31:869–873. doi:10.1183/09031936.0011170718216052
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943. doi:10.1136/thx.2009.11366219703830
   PubMed Web of Science ®Google Scholar
• Schauer GL, Wheaton AG, Malarcher AM, et al. Smoking prevalence and cessation characteristics among U.S. adults with and without COPD: findings from the 2011 behavioral risk factor surveillance system. COPD. 2014;11:697–704. doi:10.3109/15412555.2014.89804924841392
   PubMedGoogle Scholar
• World Health Organization. Household air pollution and health. Fact sheets (8 May 2018). Available from: https://www.who.int/news-room/fact-sheets/detail/household-air-pollution-and-health. Accessed 130, 2019.
   Google Scholar
• Kilic H, Kokturk N, Sari G, et al. Do females behave differently in COPD exacerbation? Int J Chron Obstruct Pulmon Dis. 2015;10:823–830. doi:10.2147/COPD.S7895225977604
   PubMed Web of Science ®Google Scholar
• Greulich T, Weist BJD, Koczulla AR, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir Med. 2017;132:132–138. doi:10.1016/j.rmed.2017.10.00729229085
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Price D, Rabe KF, et al. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:549–564. doi:10.2147/COPD25834416
   PubMed Web of Science ®Google Scholar
• Gunen H, Yilmaz M, Aktas O, et al. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study. Int J Chron Obstruct Pulmon Dis. 2015;10:2485–2494. doi:10.2147/COPD26622176
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Worth H, Soler Cataluña JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.25331383
   PubMed Web of Science ®Google Scholar
• Fragoso E, André S, Boleo-Tomé JP, et al. Understanding COPD: a vision on phenotypes, comorbidities and treatment approach. Rev Port Pneumol (2006). 2016;22:101–111. doi:10.1016/j.rppnen.2015.12.00126827246
   PubMed Web of Science ®Google Scholar
• Arkhipov V, Arkhipova D, Miravitlles M, et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017;12:3255–3262. doi:10.2147/COPD29138554
   PubMed Web of Science ®Google Scholar
• Di Marco F, Santus P, Scichilone N, et al. Symptom variability and control in COPD: advantages of dual bronchodilation therapy. Respir Med. 2017;125:49–56. doi:10.1016/j.rmed.2017.03.00128340862
   PubMed Web of Science ®Google Scholar
• Wu M, Wang Z, Li M, et al. Daily symptom variability in patients with stable COPD: a narrative review. West J Nurs Res. 2018;40:1543–1561. doi:10.1177/019394591770513228459177
   PubMed Web of Science ®Google Scholar
• Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–2048. doi:10.1185/0300799090310300619569976
   PubMed Web of Science ®Google Scholar
• Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112. doi:10.1186/1465-9921-14-11224143997
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee BK, Jung CY, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study. Korean J Intern Med. 2012;27:426–435. doi:10.3904/kjim.2012.27.4.42623269884
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18:67. doi:10.1186/s12931-017-0548-328431503
   PubMed Web of Science ®Google Scholar
• Núñez A, Esquinas C, Barrecheguren M, et al. Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire. Int J Chron Obstruct Pulmon Dis. 2018;13:3837–3844. doi:10.2147/COPD30538445
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• van Buul AR, Kasteleyn MJ, Chavannes NH, Taube C. Morning symptoms in COPD: a treatable yet often overlooked factor. Expert Rev Respir Med. 2017;11(4):311–322. doi:10.1080/17476348.2017.130589428282500
   PubMed Web of Science ®Google Scholar
• Kokturk N, Polatli M, Oguzulgen IK, et al. Adherence to COPD treatment in Turkey and Saudi Arabia: results of the ADCARE study. Int J Chron Obstruct Pulmon Dis. 2018;27:1377–1388.
   Web of Science ®Google Scholar